Vivani Medical, Inc.
No SEC Form 4 filings for $VANI in the last 30 days.
See all $VANI insider activity →Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglut
Vivani Medical (VANI) awards 70,000 options and 35,000 RSUs to CBO Rhea-AI Filing Summary Vivani Medical, Inc. granted Chief Business Officer Donald Dwyer equity awards consisting of stock options and performance-based RSUs. He received 70000.0000 common stock options with a 10-year term and a 1.3100 exercise price, vesting 25% after one year and monthly over 36 months, subject to continued service.
Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.
Over the past 7 days, alphai's AI scored 1 news story mentioning VANI (Vivani Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VANI coverage spans financial news, earnings and insider activity.
Near-term catalyst is November 2026 SLIM-1 top-line data, with additional optionality from a Novo Nordisk non-exclusive evaluation agreement and a planned Cortigent spin/merger financing path.
The disclosure is a routine equity-compensation grant with a performance hurdle, offering limited near-term trading signal.
The filing is a primary-source insider purchase, but it is not accompanied by new company fundamentals or guidance.
The Novo Nordisk evaluation agreement and planned first-in-human Phase 1 start are incremental but tangible catalysts for Vivani’s GLP-1 implant program.
The Novo Nordisk evaluation agreement is a meaningful validation step for Vivani’s semaglutide implant program and NanoPortal platform.
alphai scores every news story that mentions VANI with an AI model for sentiment and relevance, and aggregates insider trades from Vivani Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglut
7 min readVivani Medical (VANI) awards 70,000 options and 35,000 RSUs to CBO Rhea-AI Filing Summary Vivani Medical, Inc. granted Chief Business Officer Donald Dwyer equity awards consisting of stock options and performance-based RSUs. He received 70000.0000 common stock options with a 10-year term and a 1.3100 exercise price, vesting 25% after one year and monthly over 36 months, subject to continued service.
2 min readWilliams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.
2 min readVivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. The companies noted no exclusivity. Vivani expects to start a Phase 1 first-in-human trial in mid-2026, comparing with Wegovy, to support a Phase 2 dose-ranging study.
3 min readVivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.
2 min readVivani Medical (Nasdaq: VANI) said it agreed with Novo Nordisk to conduct a non-exclusive internal evaluation of Vivani’s NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. The companies did not disclose financial terms or timelines.
2 min readVivani Medical (Nasdaq: VANI) said it signed a non-exclusive agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139, a miniature ultra long-acting semaglutide implant using Vivani’s NanoPortal platform, for chronic weight management. Vivani expects to start a Phase 1 first-in-human study in mid-2026 using Wegovy as comparator.
3 min readVivani Medical (Nasdaq: VANI) said it signed a non-exclusive agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Vivani expects to start a Phase 1 first-in-human trial of NPM-139 mid-2026, using Wegovy as an active comparator.
4 min readVivani Medical, Inc. (VANI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 7 ex21_1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG CLEARONE INC., CLRO MERGER SUB, INC., CORTIGENT, INC. AND VIVANI MEDICAL, INC. Dated as of July 1, 2026 TABLE OF CONTENTS Page ARTICLE 1 DESCRIPTION OF TRANSACTION 2 1.1 Structure of the Merger
2 min readVivani Medical’s subsidiary Cortigent will merge with ClearOne, with ClearOne renamed Cortigent Holdings and expected to trade on Nasdaq under ticker CRGT. ClearOne will raise $10M–$15M via concurrent financing. Vivani will receive 12.5M shares and is expected to own 59.4%–67.5% of the combined company; former ClearOne holders 12.7%–14.4%.
4 min read
